PASITHEA THERAPEUTICS CORP. (KTTA)
Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
📈 **POSITIVE** • Medium confidence analysis (65%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (86%) **Content type:** Clinical